Table 5.

Short-term clinical outcomes in the model-concordant and model-nonconcordant groups.

Short-term outcomes			Samples, n		Before adjustment				After propensity score weighting adjustment
					Incidence, n (%)		P value		ORa		95% CI		P value
Antiglycemic treatmentb (HbA1c)c <7%)							<.001		1.73		1.69-1.76		<.001
	Concordant	78,670		48,263 (61.35)
	Nonconcordant	99,819		21,507 (21.55)
Antihypertensive treatmentd (SBPe/DBPf<140/90 mmHg)							<.001		1.26		1.23-1.29		<.001
	Concordant	80,868		62,058 (76.74)
	Nonconcordant	64,037		35,327 (55.17)
Lipid-lowering treatmentg (LDL-ch<2.6 mmol/L)							<.001		1.28		1.22-1.35		<.001
	Concordant	14,985		10,702 (71.42)
	Nonconcordant	18,097		10,028 (55.41)
Antiglycemic treatmenti (Hypoglycemia in next 6 months)							<.001		0.97		0.91-1.02		0.22
	Concordant	113,343		1497 (1.32)
	Nonconcordant	148,405		3009 (2.03)

^aOR: odds ratio.

^bConfounders considered: age, gender, ethnicity, smoking, duration of diabetes, HbA_1c, SBP/DBP, LDL-c, triglycerides (TG), BMI, estimated glomerular filtration rate (eGFR), hypertension, hypercholesterolemia, macrovascular complication, microvascular complication, hypoglycemia history.

^cHbA_1c: glycated hemoglobin A_1c.

^dConfounders considered: age, gender, ethnicity, smoking, duration of diabetes, HbA_1c, SBP/DBP, LDL-c, TG, BMI, eGFR, hypercholesterolemia, myocardial infarction, unstable angina, heart failure, stroke, nephropathy.

^eSBP: systolic blood pressure.

^fDBP: diastolic blood pressure.

^gConfounders considered: age, gender, ethnicity, smoking, duration of diabetes, HbA_1c, SBP/DBP, LDL-c, TG, BMI, eGFR, alanine transaminase, macrovascular complication, nephropathy.

^hLDL-c: low-density lipoprotein cholesterol.

ⁱConfounders considered: age, gender, ethnicity, smoking, duration of diabetes, HbA_1c, SBP, LDL-c, BMI, serum creatinine, hypertension, atrial fibrillation, macrovascular complication, microvascular complication.